By measuring the sero-reactivity against a panel of seven tumor-related antigens (p53, NY-ESO-1, CAGE, GBU4-5, HuD, and MAGE A4, and SOX-2), this assay yields sensitivity and specificity of 41% and 87%, respectively [75,76,77]. Here, SOX2 is linked to neoplasm.